OBJECTIVE: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19). METHODS: We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1：1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered online (NCT04261517). RESULTS: One patient in HCQ group developed to severe during the treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group (P>0.05). The median duration from hospitalization to virus nucleic acid negative conservation was 4 (1,9) days in HCQ group, which is comparable to that in the control group [2 (1,4) days, Z=1.27, P>0.05]. The median time for body temperature normalization in HCQ group was 1 (0,2) day after hospitalization, which was also comparable to that in the control group [1 (0,3) day]. Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all patients showed improvement in follow-up examinations. Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (P>0.05). CONCLUSIONS: The prognosis of COVID-19 moderate patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size.
OBJECTIVE: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19). METHODS: We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1：1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered online (NCT04261517). RESULTS: One patient in HCQ group developed to severe during the treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group (P>0.05). The median duration from hospitalization to virus nucleic acid negative conservation was 4 (1,9) days in HCQ group, which is comparable to that in the control group [2 (1,4) days, Z=1.27, P>0.05]. The median time for body temperature normalization in HCQ group was 1 (0,2) day after hospitalization, which was also comparable to that in the control group [1 (0,3) day]. Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all patients showed improvement in follow-up examinations. Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (P>0.05). CONCLUSIONS: The prognosis of COVID-19 moderate patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size.
Authors: F Chen; Y T Hao; Z J Zhang; J L Tang; J L Xia; S Y Zhan; Y Zhao; Z C Du; Y Y Wei; S P Shen; Q W Jiang; L M Li Journal: Zhonghua Liu Xing Bing Xue Za Zhi Date: 2020-03-10
Authors: Martin J Vincent; Eric Bergeron; Suzanne Benjannet; Bobbie R Erickson; Pierre E Rollin; Thomas G Ksiazek; Nabil G Seidah; Stuart T Nichol Journal: Virol J Date: 2005-08-22 Impact factor: 4.099
Authors: Pascale M Abena; Eric H Decloedt; Emmanuel Bottieau; Fatima Suleman; Prisca Adejumo; Nadia A Sam-Agudu; Jean-Jacques Muyembe TamFum; Moussa Seydi; Serge P Eholie; Edward J Mills; Oscar Kallay; Alimuddin Zumla; Jean B Nachega Journal: Am J Trop Med Hyg Date: 2020-06 Impact factor: 2.345
Authors: Pratik A Patel; Shanmuganathan Chandrakasan; Geoffrey E Mickells; Inci Yildirim; Carol M Kao; Carolyn M Bennett Journal: Pediatrics Date: 2020-05-04 Impact factor: 7.124
Authors: Evelyne Bischof; Alex Zhavoronkov; Jeremy M Levin; Tudor I Oprea; Sagie Davidovich; Thomas Clozel; John P Overington; Quentin Vanhaelen; Charles R Cantor Journal: Nat Biotechnol Date: 2020-10 Impact factor: 54.908
Authors: Zhikang Ye; Bram Rochwerg; Ying Wang; Neill K Adhikari; Srinivas Murthy; François Lamontagne; Robert A Fowler; Haibo Qiu; Li Wei; Ling Sang; Mark Loeb; Ning Shen; Minhua Huang; Zhaonan Jiang; Yaseen M Arabi; Luis Enrique Colunga-Lozano; Li Jiang; Younsuck Koh; Dong Liu; Fang Liu; Jason Phua; Aizong Shen; Tianyi Huo; Bin Du; Suodi Zhai; Gordon H Guyatt Journal: CMAJ Date: 2020-10-26 Impact factor: 8.262
Authors: Byeong Yun Ahn; Chang Kyung Kang; Jong Do Seo; Pyoeng Gyun Choe; Sang Hoon Song; Wan Beom Park; Sang Won Park; Nam Joong Kim; Myoung Don Oh Journal: J Korean Med Sci Date: 2020-06-22 Impact factor: 2.153
Authors: Meghan E Sise; Meridale V Baggett; Jo-Anne O Shepard; Jacob S Stevens; Eugene P Rhee Journal: N Engl J Med Date: 2020-05-13 Impact factor: 91.245